More Clinuvel Pharmaceuticals Limited news
Clinuvel Pharmaceuticals LimitedASX: CUV

FDA accept SCENESSE clinical data package for NDA submission

Jul 18, 2016 at 12:24 AM EDT · Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · Jul 18, 2016 at 12:24 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/fda-accept-scenesse-clinical-data-package-for-nda-submission

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27↗

Clinuvel Pharmaceuticals Limited on 6ix

Story so far

  • FDA awards SCENESSE Fast Track designation for EPP treatmentJul 6, 2016
  • SCENESSE launched in EuropeJun 22, 2016
  • SCENESSE Treatment in EuropeMay 18, 2016

Earlier from Clinuvel Pharmaceuticals

  • FDA awards SCENESSE Fast Track designation for EPP treatmentJul 5, 2016
  • SCENESSE launched in EuropeJun 22, 2016
  • SCENESSE Treatment in EuropeMay 18, 2016
  • SCENESSE attains breakthrough European Market AuthorisationMar 30, 2016
  • US patent for alpha-MSH and analoguesMar 30, 2016

Later from Clinuvel Pharmaceuticals

  • Clinuvel completes combination therapy pre-clinical studyAug 3, 2016
  • FDA Schedules Pre-NDA Meeting for SCENESSEOct 12, 2016
  • SCENESSE - NICE England UpdateOct 17, 2016
  • CLINUVEL agrees with FDA on New Drug Application timelinesNov 8, 2016
  • CLINUVEL reaches agreement on German SCENESSE pricingApr 12, 2017
All Clinuvel Pharmaceuticals news releases↗

Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.

Follow Clinuvel Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer